The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Cannabinoids Elicit Antidepressant-Like Behavior and Activate Serotonergic Neurons through the Medial Prefrontal Cortex
Open accessAbstract
Preclinical and clinical studies show that cannabis modulates mood and possesses antidepressant-like properties, mediated by the agonistic activity of cannabinoids on central CB 1 receptors (CB 1 Rs). The action of CB 1 R agonists on the serotonin (5-HT) system, the major transmitter system involved in mood control and implicated in the mechanism of action of antidepressants, remains however poorly understood. In this study, we demonstrated that, at low doses, the CB 1 R agonist WIN55,212-2 [R(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl) methanone mesylate] exerts potent antidepressant-like properties in the rat forced-swim test (FST). This effect is CB 1 R dependent because it was blocked by the CB 1 R antagonist rimonabant and is 5-HT mediated because it was abolished by pretreatment with the 5-HT-depleting agent parachlorophenylalanine. Then, using in vivo electrophysiology, we showed that low doses of WIN55,212-2 dose dependently enhanced dorsal raphe nucleus 5-HT neuronal activity through a CB 1 R-dependent mechanism. Conversely, high doses of WIN55,212-2 were ineffective in the FST and decreased 5-HT neuronal activity through a CB 1 R-independent mechanism. The CB 1 R agonist-induced enhancement of 5-HT neuronal activity was abolished by total or medial prefrontocortical, but not by lateral prefrontocortical, transection. Furthermore, 5-HT neuronal activity was enhanced by the local microinjection of WIN55,212-2 into the ventromedial prefrontal cortex (mPFCv) but not by the local microinjection of WIN55,212-2 into the lateral prefrontal cortex. Similarly, the microinjection of WIN55,212-2 into the mPFCv produced a CB 1 R-dependent antidepressant-like effect in the FST. These results demonstrate that CB 1 R agonists possess antidepressant-like properties and modulate 5-HT neuronal activity via the mPFCv.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is in agreement with a clinical study (Hill et al, 2008) as well as with findings in nonhuman models, in which inhibition of AEA metabolism has anxiolytic and antidepressant effects (Bambico et al, 2007;Naidu et al, 2007).”
From Acute stress increases circulating anandamide and other N-acylethanolamines in healthy humans (2012) · cites this paper as Bambico et al, 2007
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
The Rat Brain in Stereotaxic Coordinates
Paxinos, G., & Watson, C. (1983) · Elsevier eBooks · doi:10.1016/c2009-0-63235-9 · Cited by 28,585
AChE-stained horizontal sections of the rat brain in stereotaxic coordinates
Paxinos, G., WATSON, C. R. R., & Emson, P. C. (1980) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(80)90021-7 · Cited by 4,501
Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus
Malberg, J. E., Eisch, A. J., Nestler, E. J., & Duman, R. S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-24-09104.2000 · Cited by 3,111
The molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957
The endogenous cannabinoid system controls extinction of aversive memories
Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., Hermann, H., Tang, J., Hofmann, C., Zieglgänsberger, W., et al. (2002) · Nature · doi:10.1038/nature00839 · Cited by 1,728
Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system
Tsou, K., Brown, S., Sañudo-Peña, M. C., Mackie, K., & Walker, J. M. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00436-3 · Cited by 1,586
Cryan, J. F., Valentino, R. J., & Lucki, I. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.008 · Cited by 1,138
Marsicano, G., & Lutz, B. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00847.x · Cited by 937
Amat, J., Baratta, M. V., Paul, E., Bland, S. T., Watkins, L. R., & Maier, S. F. (2005) · Nature Neuroscience · doi:10.1038/nn1399 · Cited by 931
Research works printed but not linked: 2
- 10.1111/j.1460-9568.1998.00292.x · DOI
- Patel S Wang HD Hillard CJ Deutch AY International Cannabinoid Research Society (2007) 17th Annual Symposium on the Cannabinoids (June 26–30, Saint-Sauveur, Quebec, Canada), Endocannabinoid signaling modulates dendritic spine density in prefrontal cortical pyramidal cells.
Cited by
Sorted by citations
Items 101–200 of 325
Seyrek, M., Kahraman, S., Deveci, M. S., Yeşilyurt, Ö., & Dogrul, A. B. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.09.039 · Cited by 58
High Times for Painful Blues: The Endocannabinoid System in Pain-Depression Comorbidity
Fitzgibbon, M., Finn, D. P., & Roche, M. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv095 · Cited by 60
Battaglia, S., Fazio, C. D., Vicario, C. M., & Avenanti, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065926 · Cited by 56
Genaro, K., Fabris, D., Arantes, A. L. F., Zuardi, A. W., Crippa, J. A. S., & Prado, W. A. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00391 · Cited by 55
McLaughlin, R. J., Hill, M. N., & Gorzalka, B. B. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.09.055 · Cited by 53
Dogrul, A. B., Seyrek, M., Yalçın, B., & Ulugöl, A. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.01.007 · Cited by 52
Ward, S. J., & Raffa, R. B. (2011) · Obesity · doi:10.1038/oby.2011.69 · Cited by 50
Characterization of serotonin neurotransmission in knockout mice: implications for major depression
Domínguez-López, S., Howell, R. D., & Gobbi, G. (2012) · Reviews in the Neurosciences · doi:10.1515/revneuro-2012-0044 · Cited by 52
Self-citationBurstein, O., Shoshan, N., Doron, R., & Akirav, I. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.01.026 · Cited by 54
Morrish, A. C., Hill, M. N., Riebe, C. J. N., & Gorzalka, B. B. (2009) · Physiology & Behavior · doi:10.1016/j.physbeh.2009.04.023 · Cited by 49
Wu, Z., Shen, Z., Xu, Y., Chen, S., Xiao, S., Ye, J., Zhang, H., Ma, X., Zhu, Y., Zhu, X., et al. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14520 · Cited by 47
Role of the Endocannabinoid System in Depression: from Preclinical to Clinical Evidence
Micale, V., Tabiová, K., Kučerová, J., & Drago, F. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2294-9_5 · Cited by 47
Prefrontal endocannabinoids, stress controllability and resilience: A hypothesis
Worley, N. B., Hill, M. N., & Christianson, J. P. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.04.004 · Cited by 51
Recent Advances in the Realm of Allosteric Modulators for Opioid Receptors for Future Therapeutics
Remesic, M., Hruby, V. J., Porreca, F., & Lee, Y. S. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00090 · Cited by 48
Genes differentially expressed in CB1 knockout mice: Involvement in the depressive-like phenotype
Aso, E., Ozaita, A., Serra, M.-À., & Maldonado, R. J. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.06.007 · Cited by 46
Häring, M., Enk, V., Rey, A. A., Loch, S., de Azúa, I. R., Weber, T., Bartsch, D., Monory, K., & Lutz, B. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00235 · Cited by 47
The Emerging Role of the Endocannabinoid System in the Sleep-Wake Cycle Modulation
Murillo‐Rodríguez, E., Poot-Aké, A., Arias-Carrión, Ó., Pacheco-Pantoja, E. L., de la Fuente-Ortegon, A., & Arankowsky‐Sandoval, G. (2011) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/187152411798047780 · Cited by 47
Kolla, N. J., & Mishra, A. (2018) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2018.00041 · Cited by 46
Cannabinoid Actions on Neural Stem Cells: Implications for Pathophysiology
Rodrigues, R. S., Lourenço, D. M., Paulo, S. L., Mateus, J. M., Ferreira, M. F., Mouro, F. M., Moreira, J. B., Ribeiro, F. F., Sebastião, A. M., & Xapelli, S. (2019) · Molecules · doi:10.3390/molecules24071350 · Cited by 47
Liu, P., Chen, J., Ma, S., Zhang, J., & Zhou, J. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa076 · Cited by 46
Mendiguren, A., & Pineda, J. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00434.x · Cited by 44
Morgese, M. G., Cassano, T., Gaetani, S., Macheda, T., Laconca, L., Dipasquale, P., Ferraro, L., Antonelli, T., Cuomo, V., & Giuffrida, A. (2008) · Neurochemistry International · doi:10.1016/j.neuint.2008.10.007 · Cited by 44
Changes in the Brain Endocannabinoid System in Rat Models of Depression
Smaga, I., Jastrzębska, J., Zaniewska, M., Bystrowska, B., Gawliński, D., Faron‐Górecka, A., Broniowska, Ż., Miszkiel, J., & Filip, M. (2017) · Neurotoxicity Research · doi:10.1007/s12640-017-9708-y · Cited by 44
Saito, V. M., Wotjak, C. T., & Moreira, F. A. (2010) · PubMed · Cited by 43
Prospects for the Use of Cannabinoids in Psychiatric Disorders
Graczyk, M., Łukowicz, M., & Dzierżanowski, T. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.620073 · Cited by 45
Kuc, J., Kettner, H., Rosas, F. E., Erritzøe, D., Haijen, E. C. H. M., Kaelen, M., Nutt, D., & Carhart-Harris, R. L. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05999-1 · Cited by 41
Morais, H., de Souza, C. P., da Silva, L. M., Ferreira, D. M., Baggio, C. H., Vanvossen, A. C., de Carvalho, M. C., da Silva‐Santos, J. E., Bertoglio, L. J., da Cunha, J. M., et al. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.08.007 · Cited by 40
Strain-, Sex-, and Time-Dependent Antidepressant-like Effects of Cannabidiol
Silote, G. P., Gatto, M. C., Eskelund, A., Guimarães, F. S., Wegener, G., & Joca, S. R. L. (2021) · Pharmaceuticals · doi:10.3390/ph14121269 · Cited by 40
The Endocannabinoid/Endovanilloid System and Depression
Smaga, I., Bystrowska, B., Gawliński, D., Przegaliński, E., & Filip, M. (2014) · Current Neuropharmacology · doi:10.2174/1570159x12666140923205412 · Cited by 40
Gregorio, D. D., Conway, J. D., Canul, M.-L., Posa, L., Bambico, F. R., & Gobbi, G. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa058 · Cited by 38
Self-citationSmart drugs and neuroenhancement: what do we know?
Esposito, M., Cocimano, G., Ministrieri, F., Rosi, G. L., Nunno, N. R. D., Messina, G., Sessa, F., & Salerno, M. (2021) · Frontiers in Bioscience-Landmark · doi:10.52586/4948 · Cited by 39
Novel Molecular Targets of Antidepressants
Jarończyk, M., & Walory, J. (2022) · Molecules · doi:10.3390/molecules27020533 · Cited by 40
Janero, D. R., Vadivel, S. K., & Makriyannis, A. (2009) · International Review of Psychiatry · doi:10.1080/09540260902782778 · Cited by 37
Bambico, F. R., Duranti, A., Nóbrega, J. N., & Gobbi, G. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.12.027 · Cited by 41
Self-citationZádor, F., Kocsis, D., Borsodi, A. D., & Benyhe, S. (2014) · Neurochemistry International · doi:10.1016/j.neuint.2013.12.005 · Cited by 37
Haj‐Mirzaian, A., Amini-Khoei, H., Haj‐Mirzaian, A., Amiri, S., Ghesmati, M., Zahir, M., Shafaroodi, H., & Dehpour, A. R. (2017) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2017.01.018 · Cited by 38
Brain TRPV1: a depressing TR(i)P down memory lane?
Marzo, V. D., Gobbi, G., & SZALLASI, A. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.09.004 · Cited by 37
Self-citationDrug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease
Wyrofsky, R. R., McGonigle, P., & Bockstaele, E. J. V. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.966680 · Cited by 35
Salviato, B. Z., Raymundi, A. M., da Silva, T. R., Salemme, B. W., Sohn, J. M. B., de Araujo, F. S., Guimarães, F. S., Bertoglio, L. J., & Stern, C. A. J. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108684 · Cited by 35
ElBatsh, M. M., Moklas, M. A. M., Marsden, C. A., & Kendall, D. A. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.05.009 · Cited by 35
Kirilly, E., Hunyady, L., & Bagdy, G. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0900-1 · Cited by 34
Gopaldas, M., Zanderigo, F., Zhan, S., Ogden, R. T., Miller, J. M., Rubin‐Falcone, H., Cooper, T. B., Oquendo, M. A., Sullivan, G. M., Mann, J. J., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.07.035 · Cited by 33
Possible therapeutic applications of cannabis in the neuropsychopharmacology field
Fernández‐Ruíz, J., Galve‐Roperh, I., Sagredo, O., & Guzmán, M. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.01.013 · Cited by 35
Cannabinoids and Dementia: A Review of Clinical and Preclinical Data
Walther, S., & Halpern, M. (2010) · Pharmaceuticals · doi:10.3390/ph3082689 · Cited by 32
Kirkedal, C., Wegener, G., Moreira, F. A., Joca, S. R. L., & Liebenberg, N. (2016) · Acta Neuropsychiatrica · doi:10.1017/neu.2016.68 · Cited by 32
Nazzaro, C., Barbieri, M., Varani, K., Beani, L., Valentino, R. J., & Siniscalchi, A. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.09.004 · Cited by 32
Guiard, B. P., Mansari, M. E., Murphy, D. L., & Blier, P. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000484 · Cited by 32
Endocannabinoids, stress signaling, and the locus coeruleus-norepinephrine system
Wyrofsky, R. R., Reyes, B. A. S., Zhang, X.-Y., Bhatnagar, S., Kirby, L. G., & Bockstaele, E. J. V. (2019) · Neurobiology of Stress · doi:10.1016/j.ynstr.2019.100176 · Cited by 31
Medical marijuana and workers' compensation claiming
Ghimire, K., & Maclean, J. C. (2020) · Health Economics · doi:10.1002/hec.3992 · Cited by 32
Endocannabinoid-serotonin systems interaction in health and disease
Colangeli, R., Teskey, G. C., & Giovanni, G. D. (2021) · Progress in brain research · doi:10.1016/bs.pbr.2021.01.003 · Cited by 31
Sartim, A. G., Moreira, F. A., & Joca, S. R. L. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.10.031 · Cited by 31
Esteban, S., & Garcı́a-Sevilla, J. A. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.11.007 · Cited by 30
Cohen, K., Mama, Y., Rosca, P., Pinhasov, A., & Weinstein, A. M. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00602 · Cited by 30
Changes in the cannabinoids receptors in rats following treatment with antidepressants
Smaga, I., Zaniewska, M., Gawliński, D., Faron‐Górecka, A., Szafrański, P. W., Cegla, M. T., & Filip, M. (2017) · NeuroToxicology · doi:10.1016/j.neuro.2017.08.012 · Cited by 30
Morais, H., Chaves, Y. C., Waltrick, A. P. F., Jesus, C. H. A., Genaro, K., Crippa, J. A. S., da Cunha, J. M., & Zanoveli, J. M. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.06.006 · Cited by 32
Targeting the Endocannabinoid System in Psychiatric Illness
Katzman, M. A., Furtado, M., & Anand, L. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000581 · Cited by 30
Ortega, J. E., González-Lira, V., Horrillo, I., Herrera‐Marschitz, M., Callado, L. F., & Meana, J. J. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.03.043 · Cited by 29
Mitjans, M., Gastó, C., Catalán, R., Fañanás, L., & Arias, B. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112454229 · Cited by 29
Saito, V. M., Wotjak, C. T., & Moreira, F. A. (2010) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462010000500004 · Cited by 34
Miao, Y., Zhao, F., & Guan, W. (2024) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyae064 · Cited by 29
Emotional disorders induced by Hemopressin and RVD-hemopressin(α) administration in rats
Leone, S., Recinella, L., Chiavaroli, A., Martinotti, S., Ferrante, C., Mollica, A., Macedonio, G., Stefanucci, A., Dvorácskó, S., Tömböly, C., et al. (2017) · Pharmacological Reports · doi:10.1016/j.pharep.2017.06.010 · Cited by 29
Lee, T. T.-Y., Hill, M. N., Hillard, C. J., & Gorzalka, B. B. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.07.021 · Cited by 26
Cannabinoids and sleep-wake cycle: The potential role of serotonin
Vaseghi, S., Arjmandi-Rad, S., Nasehi, M., & Zarrindast, M. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113440 · Cited by 24
Multiregional profiling of the brain transmembrane proteome uncovers novel regulators of depression
Li, S., Luo, H., Lou, R., Tian, C., Chen, M., Xia, L., Pan, C., Duan, X., Dang, T., Li, H. Z., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf0634 · Cited by 26
Tao, R., & Ma, Z. (2012) · ISRN Pharmacology · doi:10.5402/2012/276902 · Cited by 25
Characterization of the biochemical and behavioral effects of cannabidiol: implications for migraine
Greco, R., Francavilla, M., Demartini, C., Zanaboni, A. M., Sodergren, M. H., Facchetti, S., Pacchetti, B., Palmisani, M., Franco, V., & Tassorelli, C. (2023) · The Journal of Headache and Pain · doi:10.1186/s10194-023-01589-y · Cited by 26
Alexandre, J., Malheiro, R. F., da Silva, D. D., Carmo, H., Carvalho, F. D., & Silva, J. P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176277 · Cited by 24
Chia, J. S. M., Farouk, A. A. O., Mohamad, T. A. S. T., Sulaiman, M. R., Zakaria, H., Hassan, N. I., & Perimal, E. K. (2021) · Molecules · doi:10.3390/molecules26133849 · Cited by 23
Comai, S., Núñez, N. A., Atkin, T., Ghabrash, M. F., Zakarian, R., Fielding, A., Saint-Laurent, M., Low, N. C. P., Sauber, G., Ragazzi, E., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03248-8 · Cited by 22
Self-citationBambico, F. R., Comai, S., Diwan, M., Hasan, S. M. N., Conway, J. D., Darvish-Ghane, S., Hamani, C., Gobbi, G., & Nóbrega, J. N. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.03.011 · Cited by 25
Self-citationMato, S., Pilar-Cuéllar, F., Valdizán, E. M., González‐Maeso, J., Rodríguez‐Puertas, R., Meana, J. J., Sallés, J., Crespo‐Facorro, B., & Pazos, Á. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.08.012 · Cited by 24
An endocannabinoid receptor polymorphism modulates affective processing under stress
Wirz, L., Reuter, M., Felten, A., & Schwabe, L. (2018) · Social Cognitive and Affective Neuroscience · doi:10.1093/scan/nsy083 · Cited by 23
Anand, D., Paquette, C., Bartuska, A. D., & Daughters, S. B. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.01.002 · Cited by 21
Miller, L. L., Ward, S. J., & Dykstra, L. (2008) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32830ded11 · Cited by 21
Cannabis abuse and severity of psychotic and affective disorders in Israeli psychiatric inpatients
Katz, G., Durst, R., Shufman, E., Bar‐Hamburger, R., & Grunhaus, L. J. (2009) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2009.03.008 · Cited by 20
Pavón, F. J., Polis, I. Y., Stouffer, D. G., Cravatt, B. F., Roberto, M., Martin‐Fardon, R., de Fonseca, F. R., Parsons, L. H., & Serrano, A. (2021) · Neurobiology of Stress · doi:10.1016/j.ynstr.2021.100293 · Cited by 18
Interaction of Cannabis Use and Aging: From Molecule to Mind
Yoo, H. B., DiMuzio, J. M., & Filbey, F. M. (2019) · Journal of Dual Diagnosis · doi:10.1080/15504263.2019.1665218 · Cited by 21
Integrating Endocannabinoid Signalling In Depression
Rana, T., Behl, T., Sehgal, A., Mehta, V., Singh, S., Kumar, R., & BUNGAU, S. G. (2021) · Journal of Molecular Neuroscience · doi:10.1007/s12031-020-01774-7 · Cited by 20
The Public Health Effects of Legalizing Marijuana
Anderson, D. M., & Rees, D. (2021) · National Bureau of Economic Research · doi:10.3386/w28647 · Cited by 19
Carnevali, L., Rivara, S., Nalivaiko, E., Thayer, J. F., Vacondio, F., Mor, M., & Sgoifo, A. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.04.013 · Cited by 18
The Potential Benefits of Palmitoylethanolamide in Palliation: A Qualitative Systematic Review
Davis, M. P., Behm, B., Mehta, Z. Y., & Fernandez, C. (2019) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/1049909119850807 · Cited by 20
Sahoo, S., Kharkar, P. S., Sahu, N. U., & Brijesh, S. (2020) · Phytotherapy Research · doi:10.1002/ptr.6900 · Cited by 18
Cannabis Use and Mental Illness: Understanding Circuit Dysfunction Through Preclinical Models
Jenkins, B. W., & Khokhar, J. Y. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.597725 · Cited by 19
Is there a role for palmitoylethanolamide in the treatment of depression?
Coppola, M., & Mondola, R. (2014) · Medical Hypotheses · doi:10.1016/j.mehy.2013.12.016 · Cited by 19
Akerele, E., & Olupona, T. (2017) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2017.05.006 · Cited by 17
Kirkedal, C., Elfving, B., Müller, H. K., Moreira, F. A., Bîndilă, L., Lutz, B., Wegener, G., & Liebenberg, N. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.01.023 · Cited by 17
Poleszak, E., Wośko, S., Sławińska, K., Wyska, E., Szopa, A., Doboszewska, U., Właź, P., Właź, A., Dudka, J., Szponar, J., et al. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.05.021 · Cited by 17
Dunn, A. L., Michie, P. T., Hodgson, D. M., & Harms, L. R. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.06.028 · Cited by 15
Richter, H., Teixeira, F. M., Ferreira, S. G., Kittel, Á., Köfalvi, A., & Sperlágh, B. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.003 · Cited by 17
Mendiguren, A., Aostri, E., Alberdi, E. M., Pérez‐Samartín, A., & Pineda, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.956886 · Cited by 13
Martín-González, E., Prados-Pardo, Á., Mora, S., Flores, P., & Moreno, M. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4819-y · Cited by 16
Belmont, O. A., Meléndez, A. L. B., Ruiz‐Contreras, A. E., Méndez‐Díaz, M., & Prospero-Garcia, O. E. (2019) · Brain Research · doi:10.1016/j.brainres.2019.146485 · Cited by 14
DeVuono, M. V., Caprara, O. L., Petrie, G. N., Limebeer, C. L., Rock, E. M., Hill, M. N., & Parker, L. A. (2020) · Cannabis and Cannabinoid Research · doi:10.1089/can.2020.0083 · Cited by 14
Jahanshahi, A., Maître, E. L., Temel, Y., Lanfumey, L., Hamon, M., Lesch, K., Tordera, R. M., Rı́o, J. D., Aso, E., Maldonado, R. J., et al. (2011) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2011.05.015 · Cited by 14
DeVuono, M. V., Caprara, O. L., Sullivan, M. T., Bath, A., Petrie, G. N., Limebeer, C. L., Rock, E. M., Hill, M. N., & Parker, L. A. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05529-5 · Cited by 15
Cannabinoids modulate cell survival in embryoid bodies
Nones, J., Spohr, T. C. L. S., Furtado, D. R., Sartore, R., Paulsen, B. S., Guimarães, M. Z. P., & Rehen, S. K. (2009) · Cell Biology International · doi:10.1042/cbi20090036 · Cited by 14
Vulnerability Factors for the Psychiatric and Behavioral Effects of Cannabis
Bortolato, M., Bini, V., & Tambaro, S. (2010) · Pharmaceuticals · doi:10.3390/ph3092799 · Cited by 17
Zarate, J., Churruca, I., Echevarría, E., Casis, L., de Jesús, M. L., del Burgo, L. S., & Sallés, J. (2008) · Brain Research · doi:10.1016/j.brainres.2008.07.100 · Cited by 14
Should oncologists trust cannabinoids?
Creangă-Murariu, I., Filipiuc, L.-E., Cuciureanu, M. D., Tamba, B.-I., & Alexa‐Stratulat, T. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1211506 · Cited by 13
Exploratory study of the psychopathological profiles of adolescent cannabis users
Chabrol, H., Chauchard, É., Goutaudier, N., & van Leeuwen, N. (2012) · Addictive Behaviors · doi:10.1016/j.addbeh.2012.05.005 · Cited by 13
Metadata
- Authors
- Bambico, F. R., Katz, N., Debonnel, G., & Gobbi, G.
- Affiliations
- McGill University (CA)
- Institut universitaire en santé mentale de Montréal (CA)
- Corresponding author
- Gobbi, Gabriella
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2007-10-24
- Volume
- 27
- Issue
- 43
- Pages
- 11700-11711
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- PMC
- PMC6673235
- OpenAlex
- W2073174105
- Cited by
- 325
- References
- 81
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 14 · 2023: 12 · 2022: 15 · 2021: 27 · 2020: 20 · 2019: 19 · 2018: 20 · 2017: 14 · 2016: 13 · 2015: 13 · 2014: 15 · 2013: 14 · 2012: 27
- FWCI
- 13.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- McGill University
- McGill University Health Centre
- Canadian Psychiatric Research Foundation
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- cannabinoids, CB1 receptor agonists, WIN 55,212-2, antidepressant-like behavior, serotonin, dorsal raphe nucleus, ventromedial prefrontal cortex, forced swim test, rimonabant, p-chlorophenylalanine, depression
- MeSH terms
- Animals, Antidepressive Agents, Cannabinoids, Depression, Male, Morpholines, Naphthalenes, Neurons, Serotonin, Rats, Sprague-Dawley, Prefrontal Cortex, Receptor, Cannabinoid, CB1, Benzoxazines, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
